Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2CNS 1

Conditions

Glioblastoma 39Melanoma 34Gliosarcoma 34Brain Neoplasms 33Breast Neoplasms 31Lymphoma 24Neoplasm Metastasis 23Astrocytoma 23Colonic Neoplasms 20Multiple Myeloma 19Leukemia, Myeloid, Acute 19Leukemia 19Carcinoma, Non-Small-Cell Lung 19Prostatic Neoplasms 18Lymphoma, Non-Hodgkin 18Colorectal Neoplasms 18Central Nervous System Neoplasms 18Carcinoma, Renal Cell 18Rectal Neoplasms 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Neoplasms 17Lymphoma, Large B-Cell, Diffuse 17Leukemia, Lymphocytic, Chronic, B-Cell 16Hodgkin Disease 16Squamous Cell Carcinoma of Head and Neck 15Oligodendroglioma 15Pancreatic Neoplasms 14Myelodysplastic Syndromes 14Lung Neoplasms 14Sarcoma 13

Interventions

ganitumab 1efineptakin alfa 1Receptor Protein-Tyrosine Kinases 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × NIH × Rhabdomyosarcoma, Embryonal × Clear all
NCT03041701 2022-04-14

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
14 enrolled 17 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

NCT00923351 2018-06-15

Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
44 enrolled 13 charts
CNSSarcoma

Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡